Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rapid avian flu test gains FDA go-ahead

This article was originally published in The Gray Sheet

Executive Summary

FDA clears biopharmaceutical firm Arbor Vita Corporation's AVantage A/H5N1 rapid avian flu test April 7. AVantage detects a protein that indicates the presence of the A/H5N1 influenza virus subtype, which has caused the largest number of detected cases of serious influenza infections in humans. The test takes about 40 minutes and involves a throat or nose swab collected from patients with flu-like symptoms. Previous tests for the virus subtype took three to four hours, FDA notes. Arbor Vita plans to launch the test by the end of September
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT027324

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel